Tag Archives: Pfizer

Array’s colorectal cancer data shows why Pfizer splashed out $11B for the biotech

One key incentive for Pfizer paying $ 11 billion for Array BioPharma was the positive early readouts from its triplet therapy for colorectal cancer. Now, the biotech has shown exactly how attractive that data are. A combination of Array’s BRAF inhibitor Braftovi, its MEK inhibitor Mektovi and the anti-EGFR drug Erbitux significantly extended lives of previously-treated patients… Read More »

Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure

Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »

Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment

More than a month after Mylan and Pfizer reported to Health Canada that there are new issues affecting some EpiPens, the companies and the FDA notified U.S. healthcare providers of the problem which can delay treatment when the pens are needed. Mylan, Pfizer and the FDA Friday reported that some pens and their authorized generic… Read More »